Kailera (KLRA) CCO Jamie Coleman Receives 150,000-Share Option Award

What Happened

• Jamie Coleman, Chief Commercial Officer of Kailera Therapeutics (KLRA), received two award grants on April 16, 2026 — 75,000 and 75,000 derivative shares (total 150,000) reported as acquisitions at $0.00. These are compensation awards (derivative securities), not open-market purchases or sales.

Key Details

• Transaction date: April 16, 2026; filing date: April 20, 2026 (timely Form 4 filing).
• Grants: 75,000 + 75,000 derivative awards; price reported $0.00 (no cash paid at grant).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Vesting/conditions:
  • Time-based award (Footnote F1): 25% vests on April 16, 2027, then the remainder vests in 36 substantially equal monthly installments thereafter, subject to continued service.
  • Performance-based award (Footnote F2): Vests in full if the 30-day average Nasdaq closing price reaches $40 during Oct 16, 2026–Apr 16, 2030 (or upon a qualifying change-in-control) and subject to continued service.
• Transaction type code: Reported as "A" (award/grant) and listed as derivative securities.

Context

• These awards are compensation grants rather than market purchases; they become valuable only if/when they vest and, for the performance award, if the $40 price hurdle is met. Retail investors should view this as executive compensation activity (common for hires/retention) rather than a direct bullish buy signal.